An overview on the role of silica-based materials in vaccine development

Expert Review of Vaccines

Volumn 15, Issue 11, 2016, Pages 1449-1462

  Navarro Tovar, Gabriela ^a   Palestino, Gabriela ^a   Rosales Mendoza, Sergio ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

adjuvanticity; administration route; cellular response; humoral response; immunogenicity; mucosal vaccination; particulate antigen; Silica particles

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ALUMINUM SALT; CHITOSAN; LIPOSOME; SILICA NANOPARTICLE; SILICATE; SILICON DIOXIDE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; VACCINE;

ADJUVANT THERAPY; CELL ENCAPSULATION; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPH NODE; MICROEMULSION; MOUSE; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PINOCYTOSIS; PRIORITY JOURNAL; REVIEW; VACCINATION; ANIMAL; ANIMAL MODEL; HUMAN; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; HUMANS; MODELS, ANIMAL; NANOPARTICLES; SILICON DIOXIDE; VACCINES;

EID: 84991671998     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1188009     Document Type: Review

References (122)

1. S.Wicker, H.C.Maltezou Vaccine-preventable diseases in Europe:where do we stand? Expert Rev Vaccines. 2014;13:979–987.
2. M.Kaddar, S.Schmitt, M.Makinen, et al. Global support for new vaccine implementation in middle-income countries. Vaccine. 2013;31(Suppl 2):B81–96.
3. R.F.Khabbaz, R.R.Moseley, R.J.Steiner, et al. Challenges of infectious diseases in the USA. Lancet. 2014;384:53–63.
4. H.Patel, C.Yewale, M.N.Rathi, et al. Mucosal immunization:a review of strategies and challenges. Crit Rev in Ther Drug. 2014;31:273–303.• Identifies critical aspects for mucosal vaccine development.
5. C.J.H.Davitt, E.C.Lavelle. Delivery strategies to enhance oral vaccination against enteric infections. Adv Drug Deliver Rev. 2015;91:52–69. doi:10.1016/j.addr.2015.03.007.
6. C.Ranasinghe. New advances in mucosal vaccination. Immunol Lett. 2014;161:204–206.
7. N.Mody, R.Sharma, U.Agrawal, et al. Nanocarriers:a versatile approach for mucosal vaccine delivery. Ther Deliv. 2015;6:231–45.• Highlights the potential use of nanomaterials for mucosal vaccine formulations.
8. H.Brochu, A.Polidori, B.Pucci, et al. Drug delivery systems using immobilized intact liposomes:a comparative and critical review. Current Drug Delivery. 2004;1:299–312.
9. Y.Fujkuyama, D.Tokuhara, K.Kataoka, et al. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines. 2012;11:367–379.
10. A.Lanzavecchia. Mechanisms of antigen uptake for presentation. Curr Opin Immunol. 1996;8:348–354.
11. M.Bruewer, M.Utech, A.I.Ivanov, et al. Interferon-gamma induces internalization of epithelial tight junction proteins via a macropinocytosis-like process. Fed Amer Soc Exp Biol. 2005;19:923–933.
12. R.B.J.Aylward, J.S.Lloyd, M.Zaffran, et al. Reducing the risk of unsafe injections in immunization programmes:financial and operational implications of various injection technologies. Bull World Health Organ. 1995;73(4):531–540.
13. D.T.O’Hagan, C.B.Fox. New generation adjuvants – from empiricism to rational design. Vaccine. 2015;33:B14–20.• A review that covers the importance and advances in adjuvants development.
14. A.Mittal, K.Schulze, T.Ebensen, et al. Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation. Nanomed-Nanotechnol. 2015;11:147–154.
15. A.Gebert, H.J.Rothkötter, R.Pabst. M cells in Peyer’s patches of the intestine. Int Rev Cytol. 1996;167:91–159.
16. A.C.Soloff, S.M.Barratt-Boyes. Enemy at the gates:dendritic cells and immunity to mucosal pathogens. Cell Res. 2010;20:872–85.• Highlights the role of DCs in vaccination.
17. B.Johansson-Lindbom, W.W.Agace. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev. 2007;215:226–242.
18. M.Bemark, P.Boysen, N.Y.Lycke. Induction of gut IgA production through T cell-dependent and T cell-independent pathways. Ann NY Acad Sci. 2012;1247:97–116.
19. C.Czerkinsky, J.Holmgren. Mucosal delivery routes for optimal immunization:targeting immunity to the right tissues. Curr Top Microbiol Immunol. 2012;354:1–18.• Describes the mechanisms behind effective mucosal immunization approaches.
20. C.Siewert, A.Menning, J.Dudda, et al. Induction of organ-selective CD4+ regulatory T cell homing. European J Immunol. 2007;37:978–989.
21. W.A.Goodman, T.T.Pizarro. Regulatory cell populations in the intestinal mucosa. Curr Opin Gastroenterol. 2013;29:614–620.
22. X.Wang, A.Sherman, G.Liao, et al. Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev. 2013;65:759–773.
23. D.Newsted, F.Fallahi, A.Golshani, et al. Advances and challenges in mucosal adjuvant technology. Vaccine. 2015;33:2399–2405.
24. E.Aznar, M.Oroval, L.Pascual, et al. Gated materials for on-command release of guest molecules. Chem Rev. 2016;116:561–718.
25. E.M.Varypataki, A.L.Silva, C.Barnier-Quer, et al. Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity:A comparative study of cationic liposomes and PLGA nanoparticles. J Control Release. 2016;226:98–106.
26. R.Kumar, P.C.Ray, D.Datta, et al. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles. Vaccine. 2015;33:5064–5071.
27. S.Casciaro, F.Conversano, A.Ragusa, et al. Optimal enhancement configuration of silica nanoparticles for ultrasound imaging and automatic detection at conventional diagnostic frequencies. Invest Radiol. 2010;45:715–724.
28. A.Pourjavadi, Z.M.Tehrani. Mesoporous silica nanoparticles with bilayer coating of poly(acrylic acid-co-itaconic acid) and human serum albumin (HSA):A pH-sensitive carrier for gemcitabine delivery. Delivery Mater Sci Eng Mater Biol Appl. 2016;61:782–790.
29. H.Vergara-Castañeda, A.R.Hernandez-Martinez, M.Estevez, et al. Quercetin conjugated silica particles as novel biofunctional hybrid materials for biological applications. J Colloid Interface Sci. 2016;466:44–55.
30. X.Xie, F.Li, H.Zhang, et al. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur J Pharmaceutical Sci. 2016;83:28–35.
31. M.A.Shah, Z.Ali, R.Ahmad, et al. DNA mediated vaccines delivery through nanoparticles. J Nanosci Nanotechnol. 2015;15:41–53.
32. J.Guzman, B.C.Gates. Supported molecular catalysts:metal complexes and clusters on oxides and zeolites. Dalton Trans. 2003;2003:3303–3318.
33. Y.Chen, H.-R.Chen, J.-L.Shi. Construction of homogenous/heterogeneous hollow mesoporous silica nanostructures by silica-etching chemistry:principles, synthesis, and applications. Acc Chem Res. 2014;47:125–137.
34. W.Stöber, A.Fink, E.Bohn. Controlled growth of monodisperse silica spheres in the micron size range. J Coll Interface Sci. 1968;26:62–9.•• Contains a classic method for SSN synthesis.
35. K.Nozawa, H.Gailhanou, L.Raison, et al. Smart control of monodisperse Stöber silica particles:effect of reactant addition rate on growth process. Langmuir. 2005;21:1516–1523.
36. H.Ow, D.R.Larson, M.Srivastava, et al. Bright and stable core−shell fluorescent silica nanoparticles. Nano Lett. 2005;5:113–117.
37. A.Van Blaaderen, A.Vrij. Synthesis and characterization of monodisperse colloidal organo-silica spheres. J Coll Interface Sci. 1993;156:1–18.•• Describes a methodology to achieve MSN and polymer particles.
38. A.Yari, M.Saidikhah. Dye doped Eosin yellowish silica nanoparticles as novel fluorophore for a peroxyoxalate chemiluminescence system. J Fluoresc. 2012;22:993–1002.
39. L.M.Liz-Marzán, M.Giersig, P.Mulvaney. Synthesis of nanosized gold−silica core−shell particles. Langmuir. 1996;12:4329–4335.
40. Y.Xiong, C.Deng, X.Zhang, et al. Designed synthesis of aptamer-immobilized magnetic mesoporous silica/Au nanocomposites for highly selective enrichment and detection of insulin. Appl Mater Interfaces. 2015;7:8451–8456.
41. Y.Kobayashi, S.Saeki, M.Yoshida, et al. Synthesis of spherical submicron-sized magnetite/silica nanocomposite particles. J Sol-Gel Sci Techn. 2007;45:35–41.
42. A.Ahmed, R.Clowes, E.Willneff, et al. Porous silica spheres in macroporous structures and on nanofibres. Philos Trans A, Math Phys Eng Sci. 2010;368:4351–4370.
43. M.Boutonnet, J.Kizling and P.Stenius The preparation of monodisperse colloidal metal particles from microemulsions. Colloids Surf. 1982;5:209–225.
44. F.X.Chen, G.Q.Xu, T.S.A.Hor. Preparation and assembly of colloidal gold nanoparticles in CTAB-stabilized reverse microemulsion. Mat Sci Multidisciplinary. 2003;57:3282–3286.
45. 3 particles. J Colloid Interface Sci. 1988;122:78–82.
46. F.Huang, S.Li, J.Song, et al. Complex calcium carbonate aggregates:controlled crystallization and assembly via an additive-modified positive-microemulsion-route. CrystEngComm. 2012;14:1277–1282.
47. M.T.Carver, E.Hirsch, J.C.Wittmann, et al. Percolation and particle nucleation in inverse microemulsion polymerization. J Phys Chem. 1989;93:4867–4873.
48. 2 nanoparticles in a non-ionic reverse micellar system. J Colloids Surf. 1990;50:321–339.
49. F.J.Arriagada, K.Osseo-Asare. Synthesis of nanosize silica in a nonionic water-in-oil microemulsion:effects of the water/surfactant molar ratio and ammonia concentration. J Colloid Interface Sci. 1999;211:210–220.
50. H.Gustafsson, S.Isaksson, A.Altskar, et al. Mesoporous silica nanoparticles with controllable morphology prepared from oil-in-water emulsions. J Colloid Interface Sci. 2016;467:253–260.
51. I.Roy, T.Y.Ohulchanskyy, H.E.Pudavar, et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs:a novel drug−carrier system for photodynamic therapy. J Amer Chem Soc. 2003;125:7860–7865.
52. R.K.Sharma, S.Sharma, S.Dutta, et al. Silica-nanosphere-based organic–inorganic hybrid nanomaterials:synthesis, functionalization and applications in catalysis. Green Chem. 2015;17:3207–30.•• Contains a compilation of synthesis and functionalization approaches in silica nanomaterials.
53. K.T.Mody, D.Mahony, A.S.Cavallaro, et al. Freeze-drying of ovalbumin loaded mesoporous silica nanoparticle vaccine formulation increases antigen stability under ambient conditions. Int J Pharm. 2014;465:325–332.
54. K.T.Mody, A.Popat, D.Mahony, et al. Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale. 2013;5:5167–79.•• Explores the use of silica nanoparticles in antigen delivery.
55. L.P.Mercuri, L.V.Carvalho, F.A.Lima, et al. Ordered mesoporous silica SBA-15:a new effective adjuvant to induce antibody response. Small. 2006;2:254–56.•• Describes the preclinical evaluation of an E. coli vaccine (antigen INT1β) based on SBA-15.
56. C.T.Kresge, M.E.Leonowicz, W.J.Roth, et al. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature. 1992;359:710–712.
57. D.Zhao. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science. 1998;279:548–552.
58. J.Meissner, A.Prause, C.Di Tommaso, et al. Protein immobilization in surface-functionalized SBA-15:predicting the uptake capacity from the pore structure. J Phys Chem C. 2015;119:2438–2446. doi:10.1021/jp5096745.
59. S.-I.Kim, T.T.Pham, J.-W.Lee, et al. Releasing properties of proteins on SBA-15 spherical nanoparticles functionalized with aminosilanes. J Nanosci Nanotechnol. 2010;10:3467–72.• Describes a typical methodology for covalent antigen bond.
60. S.Ajitha, S.Sugunan. Tuning mesoporous molecular sieve SBA-15 for the immobilization of α-amylase. J Porous Mater. 2010;17:341–349.
61. Y.Ding, G.Yin, X.Liao, et al. A convenient route to synthesize SBA-15 rods with tunable pore length for lysozyme adsorption. Microporous Mesoporous Mater. 2013;170:45–51.
62. N.Ž.Knežević, J.-O.Durand. Large pore mesoporous silica nanomaterials for application in delivery of biomolecules. Nanoscale. 2015;7:2199–2209.
63. Y.Wang, N.Han, Q.Zhao, et al. Redox-responsive mesoporous silica as carriers for controlled drug delivery:a comparative study based on silica and PEG gatekeepers. Eur J Pharm Sci. 2015;72:12–20.
64. J.Yang, J.Lee, J.Kang, et al. Hollow silica nanocontainers as drug delivery vehicles. Langmuir. 2008;24:3417–3421.
65. R.Vathyam, E.Wondimu, S.Das, et al. Improving the adsorption and release capacity of organic-functionalized mesoporous materials to drug molecules with temperature and synthetic methods. J Phys Chem C. 2011;115:13135–13150.
66. 1 magnetic resonance imaging and photodynamic therapy. Mater Express. 2011;1:136–143.
67. D.Skrastina, I.Petrovskis, I.Lieknina, et al. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles. PLoS ONE. 2014;9:e114006.•• Describes the preclinical evaluation of hepatitis B vaccine (antigen HBcAg forming VPLs) based on SSN.
68. T.Liu, H.Liu, C.Fu, et al. Silica nanorattle with enhanced protein loading:a potential vaccine adjuvant. J Colloid Inter Sci. 2013;400:168–174.
69. K.L.Young, A.W.Scott, L.Hao, et al. Hollow spherical nucleic acids for intracellular gene regulation based upon biocompatible silica shells. Nano Lett. 2012;12:3867–3871.
70. F.Caruso, R.Caruso, H.Mohwald. Nanoengineering of inorganic and hybrid hollow spheres by colloidal templating. Science (New York, NY). 1998;282:1111–4.•• Describes a methodology for the synthesis of HMSN.
71. B.G.Trewyn, C.M.Whitman, V.S.-Y.Lin. Morphological control of room-temperature ionic liquid templated mesoporous silica nanoparticles for controlled release of antibacterial agents. Nano Lett. 2004;4:2139–2143.
72. Y.Chen, H.Chen, L.Guo, et al. Hollow/rattle-type mesoporous nanostructures by a structural difference-based selective etching strategy. ACS Nano. 2010;4:529–539.
73. Q.Meng, S.Xiang, K.Zhang, et al. A facile two-step etching method to fabricate porous hollow silica particles. J Colloid Inter Sci. 2012;384:22–8.•• Describes a methodology for the synthesis of HMSN.
74. Y.Chen, Q.Wang, T.Wang. Facile large-scale synthesis of brain-like mesoporous silica nanocomposites via a selective etching process. Nanoscale. 2015;7:16442–16450.
75. D.M.Smith, J.K.Simon, J.R.Baker. Applications of nanotechnology for immunology. Nature Rev Immunol. 2013;13:592–605.•• A review that relates nanoparticles properties to the immune system.
76. S.D.Xiang, A.Scholzen, G.Minigo, et al. Pathogen recognition and development of particulate vaccines:does size matter? Methods. 2006;40:1–9.
77. L.Thiele, B.Rothen-Rutishauser, S.Jilek, et al. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Controlled Release. 2001;76:59–71.
78. C.Foged, B.Brodin, S.Frokjaer, et al. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298:315–22.• An in vitro study on the uptake of antigen associated with nanomaterials by DCs.
79. N.Lincopan, M.R.Santana, E.Faquim-Mauro, et al. Silica-based cationic bilayers as immunoadjuvants. BMC Biotechnol. 2009;9:5.
80. R.A.Gemeinhart, D.Luo, W.M.Saltzman. Cellular fate of a modular DNA delivery system mediated by silica nanoparticles. Biotechnol Progr. 2008;21:532–537.
81. A.Seth, F.K.Ritchie, N.Wibowo, et al. Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. PloS One. 2015;10:e0117203.•• Describes the preclinical evaluation of a porcine circovirus vaccine (antigen CapM2e) and SSN as adjuvant.
82. H.-C.Guo, X.-M.Feng, S.-Q.Sun, et al. Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein. Virol J. 2012;9:108.•• Describes the preclinical evaluation of a porcine circovirus vaccine (antigen ORF) and HMSN as adjuvant.
83. A.Heumann, C.Stiffel, L.Monjour, et al. Correlation between genetic regulation of antibody responsiveness and protective immunity induced by Plasmodium berghei vaccination. Infection and Immunity. 1979;24:829–836.
84. V.Neuhaus, K.Schwarz, A.Klee, et al. Functional testing of an inhalable nanoparticle based influenza vaccine using a human precision cut lung slice technique. PloS One. 2013;8:e71728.•• Describes the preclinical evaluation of an influenza virus vaccine (antigen HAC1) based on SSN.
85. L.Mercuri, L.V.Carvalho, F.Lima, et al. Ordered mesoporous silica SBA-15:A new effective adjuvant to induce antibody response. Small. 2006;2:254–256.
86. V.Neuhaus, J.A.Chichester, T.Ebensen, et al. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung. Vaccine. 2014;32:3216–22.•• Describes the preclinical evaluation of an influenza virus vaccine (antigen HAC1) based on SSN.
87. T.Mamo, G.A.Poland. Nanovaccinology:the next generation of vaccines meets 21st century materials science and engineering. Vaccine. 2012;30:6609–6611.
88. S.-F.Chong, A.Sexton, R.De Rose, et al. A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials. 2009;30:5178–5186.
89. M.H.Reis, O.M.Ibañez, W.H.Cabrera, et al. T-helper functions in lines of mice selected for high or low antibody production (Selection III):modulation by anti-CD4+ monoclonal antibody. Inmunology. 1992;75:80–85.
90. A.Puel, J.-C.Mevel, Y.Bouthillier, et al. Toward genetic dissection of high and low antibody responsiveness in Biozzi mice. Proc Natl Acad Sci USA. 1996;93:14742–14746.
91. L.V.Carvalho, R.D.C.Ruiz, K.Scaramuzzi, et al. Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. Vaccine. 2010;28:7829–7836.
92. X.Wang, X.Li, A.Ito, et al. Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy. Acta Biomater. 2013;9:7480–9.• Reports data on the relationship of particle size of SP and in vivo effects.
93. T.Grunwald, S.Ulbert. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices:vaccine-platforms for the battle against infectious diseases. S Clin Exp Vaccine Res. 2015;4:1–10.
94. H.Guo, R.Hao, H.Qian, et al. Upconversion nanoparticles modified with aminosilanes as carriers of DNA vaccine for foot-and-mouth disease. Appl Microbiol Biotechnol. 2012;95:1253–63.•• Describes the preclinical evaluation of an FMD virus DNA vaccine (antigen VP1) based on monodisperse silica-coated particles.
95. G.Ramon. On the properties of diphtheria toxoid. Cr Hebd Acad Sci. 1924;179:422–425.
96. G.Ramon. Toxoids. Cr Hebd Acad Sci. 1924;178:1436–1439.
97. A.García, J.B.De Sanctis. An overview of adjuvant formulations and delivery systems. APMIS:Acta Pathol Microbiol Immunol Scand. 2014;122:257–267.
98. E.Phillips, O.Penate-Medina, P.B.Zanzonico, et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med. 2014;6:260ra149.
99. A.Tan, N.G.Eskandar, S.Rao, et al. First in man bioavailability and tolerability studies of a silica-lipid hybrid (Lipoceramic) formulation:a phase I study with ibuprofen. Drug Deliv Transl Res. 2014;4:212–21.• Contains the results of the first clinical trials for a pharmaceutical formulation containing silica nanoparticles.
100. C.Kneuer, M.Sameti, U.Bakowsky, et al. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconjugate Chem. 2000;11:926–932.
101. C.Kneuer, M.Sameti, E.G.Haltner, et al. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. Int J Pharma. 2000;196:257–261.
102. K.T.Mody, D.Mahony, J.Zhang, et al. Silica vesicles as nanocarriers and adjuvants for generating both antibody and T-cell mediated immune resposes to bovine viral diarrhoea virus E2 protein. Biomaterials. 2014;35:9972–83.•• Describes the preclinical evaluation of a bovine viral diarrhea virus vaccine (antigen OE2) based on MSN.
103. T.Wang, H.Jiang, Q.Zhao, et al. Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant:effect of silica architecture on immunological properties. Int J Pharma. 2012;436:351–8.•• Describes the preclinical evaluation of cancer vaccine (M. tuberculosis extract) based on MSN.
104. I.I.Slowing, J.L.Vivero-Escoto, C.-W.Wu, et al. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008;60:1278–1288.
105. J.Ho, Y.Huang, M.K.Danquah, et al. Synthesis of biodegradable polymer-mesoporous silica composite microspheres for DNA prime-protein boost vaccination. Eur J Pharm Sci. 2010;39:412–20.• Reports a DNA vaccine candidate based on a composite comprising MSN.
106. G.Wang, H.-J.Wang, H.Zhou, et al. Hydrated silica exterior produced by biomimetic silicification confers viral vaccine heat-resistance. ACS Nano. 2015;9:799–808.
107. Y.Wang, A.Yu, F.Caruso. Nanoporous polyelectrolyte spheres prepared by sequentially coating sacrificial mesoporous silica spheres. Angew Chem. 2005;44:2888–2892.
108. Z.Tao, M.P.Morrow, T.Asefa, et al. Mesoporous silica nanoparticles inhibit cellular respiration. Nano Lett. 2008;8:1517–26.• Discusses toxic effect of MSN.
109. Z.Tao, B.B.Toms, J.Goodisman, et al. Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials. Chem Res Toxicol. 2009;22:1869–80.• Provides evidence on the safety of MSN.
110. A.M.Grumezescu, E.Andronescu, A.Ficai, et al. Biocompatible magnetic hollow silica microspheres for drug delivery. Curr Org Chem. 2013;17:1029–33.• Provides evidence on the safety of MSN.
111. J.Shen, R.Xu, J.Mai, et al. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics. ACS Nano. 2013;7:9867–9880.
112. T.Yu, D.Hubbard, A.Ray, et al. In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release. 2012;163:46–54.•• Provides data on the behavior of SP in vivo.
113. A.J.Paula, D.S.T.Martinez, R.T.Araujo Júnior, et al. Suppression of the hemolytic effect of mesoporous silica nanoparticles after protein corona interaction:independence of the surface microchemical environment. J Braz Chem Soc. 2012;23:1807–1814.
114. S.P.Hudson, R.F.Padera, R.Langer, et al. The biocompatibility of mesoporous silicates. Biomaterials. 2008;29:4045–4055.
115. X.Qiu, S.Leporatti, E.Donath, et al. Studies on the drug release properties of polysaccharide multilayers encapsulated ibuprofen microparticles. Langmuir. 2001;17:5375–5380.
116. K.T.Gause, Y.Yan, J.Cui, et al. Physicochemical and immunological assessment of engineered pure protein particles with different redox states. ACS Nano. 2015;9:2433–2444.
117. L.Zhao, A.Seth, N.Wibowo, et al. Nanoparticle vaccines. Vaccine. 2014;32:327–337.
118. M.Benezra, O.Penate-Medina, P.B.Zanzonico, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011;121:2768–2780.
119. T.Gottlieb, T.Ben-Yedidia. Epitope-based approaches to a universal influenza vaccine. J Autoimmun. 2014;54:15–20.• A potential approach to expand the benefit of silica-based vaccines.
120. T.A.Röhn, M.F.Bachmann. Vaccines against non-communicable diseases. Curr Opin Immunol. 2010;22:391–396.
121. K.Sehgal, K.M.Dhodapkar, M.V.Dhodapkar. Targeting human dendritic cells in situ to improve vaccines. Immunol Lett. 2014;162:59–67.
122. L.Cohn, L.Delamarre. Dendritic cell-targeted vaccines. Front Immunol. 2014;5:255.•• A potential approach to expand the benefit of silica-based vaccines.